

Patrick Davies – CEO EBOS Group Ltd 13 October 2015

Disclaimer

The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither the EBOS Group nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect EBOS's current expectations, based on what it thinks are reasonable assumptions. EBOS gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX or ASX listing rules, EBOS is not obliged to update this presentation after its release, even if things change materially.

This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy EBOS Group securities and may not be relied upon in connection with any purchase of EBOS Group securities.

All currency amounts are in New Zealand dollars unless stated otherwise.



Introduction



If you needed access to medicine in either New Zealand or Australia over the past year — whether through your local pharmacy, in a hospital, an aged care facility or even for your pet through a vet — it's likely **EBOS** played a vital role in getting that medicine to you.


That's because, every year, **EBOS** moves millions of healthcare products and is involved in hundreds of thousands of interactions throughout the healthcare system, playing our part in improving the wellbeing of communities right across the length and breadth of both countries.



EBOS Group – Snapshot

EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care products marketer and distributor.







Comprehensive distribution network in the animal care market, with pet brands and speciality retail outlets



EBOS Group Overview

Trans-Tasman Healthcare and Animal Care portfolio

~\$2 billion

market capitalisation Dual listed on NZX and ASX

\$6.1 billion

FY15 revenue Australia 78%, NZ 22%

\$196.7 million


FY15 EBITDA Australia 81%, NZ 19%

\$133.8 million

FY15 Operating Cash Flow

\$316.9 million

Net debt at 30 June 2015



42 locations in Australia and New Zealand

> 2,400+ employees

38,000+ customers

122,000+ product SKUs





EBOS Group Overview – Market channels

HEALTHCARE

Institutional Healthcare

Contract Logistics

HEALTHCARE

ANIMAL CARE

Pet Care and Veterinary

Community Pharmacy





























Pharmacy Retail



















Consumer Products





EBOS is the trusted partner to governments, businesses and consumers across our wide range of operations in healthcare and animal care

Wholesale







Segment and Geographic earnings overview

Earnings contribution weighted to Healthcare and Australian based











Strong Financial Results in FY15











Cash Flow

EBOS has an excellent portfolio of strong cash generating businesses


NZ\$m	FY15	FY14	Var\$	Var%
EBITDA	196.7	175.4	21.3	12.1%
Interest paid	(21.9)	(27.1)	5.2	19.2%
Tax paid	(53.0)	(29.6)	(23.4)	(78.8%)
Net working capital and other movements	12.0	(4.6)	16.6	360.9%
Cash from Operating Activities	133.8	114.2	19.6	17.2%
Capital expenditure (net)	(14.5)	(30.5)	16.0	52.4%
Free Cash Flow	119.3	83.7	35.6	42.5%

Cash conversion days	Jun-15	Dec-14	Jun-14
Debtor days	47	46	45
Inventory days	35	34	35
Creditor days	58	56	55
Cash conversion days	24	24	25

- Focus on tight working capital management led to record Operating cash flow of \$133.8m being generated in FY15.
- Tax paid of \$53.0m is \$23.4m higher than last year due to the prior year being unusually low as a result of the Symbion acquisition.
- Capex in FY15 includes \$7.8m for the new Melbourne distribution centre (FY14: \$20.6m).
- Cash conversion cycle of 24 days remains industry leading.



Net Debt and Gearing



- Net Debt of \$316.9m at June 2015.
- Net Debt: EBITDA reduced to 1.6x at June 2015 (1.8x at June 2014).
- Reduction in the Gearing ratio from 24.4% at June 2014 to 23.2% at June 2015.
- Interest cover increased to 9.0x at Jun-15 (6.5x at June 2014).
- Net finance costs reduced by \$5.2m or 17.7% (constant FX).
- Ample headroom available in debt facilities to undertake further acquisitions.



EBOS strategy

- Protect and grow our market leading positions in pharmacy in both New Zealand and Australia
 - across wholesale, consumer products and pharmacy retail
- Pursue further growth in the institutional healthcare market
- Grow EBOS's portfolio of ancillary healthcare businesses
- Increase our presence in the animal care sector through the development of our own brands -Masterpet, Vitapet, BlackHawk and our Lyppard veterinary distribution business and through strategic acquisitions
- Continued investment in operational and supply chain excellence





Continue disciplined focus on appropriately priced, strategic acquisitions

Deliver superior financial returns to our shareholders



Track record of delivering shareholder value





^{*} Excludes special dividends paid



Track record of delivering shareholder value

